Table 2

Matched ORs of different outcomes associated with exposure to DPP-4i in the 6 months before index date

 Any admission for HFIncident HFRe-admission for HFAll-cause mortality
Unadjusted OR (95% CI); p valueAdjusted OR (95% CI); p valueUnadjusted OR (95% CI); p valueAdjusted OR (95% CI); p valueUnadjusted OR (95% CI); p valueAdjusted OR (95% CI); p valueUnadjusted OR (95% CI); p valueAdjusted OR (95% CI); p value
DPP-4i use0.99 (0.92 to 1.05);
p=0.6383
1.00 (0.94 to 1.07);
p=0.9832
1.01 (0.92 to 1.11);
p=0.8867
1.01 (0.92 to 1.11);
p=0.7808
1.01 (0.84 to 1.22);
p=0.8944
1.02 (0.84 to 1.22);
p=0.8745
0.93 (0.89 to 0.97);
p=0.0005
0.94 (0.90 to 0.98);
p=0.0021
Previous disorders or treatments
 Ischaemic heart disease (in the past 5 years)1.36 (1.31 to 1.40);
p=<0.0001
1.34 (1.29 to 1.38);
p=<0.0001
1.09 (1.04 to 1.14);
p=0.0003
1.08 (1.03 to 1.13);
p=0.0014
1.03 (0.96 to 1.11);
p=0.4455
1.02 (0.95 to 1.10);
p=0.6067
1.11 (1.09 to 1.14);
p=<0.0001
1.09 (1.07 to 1.12);
p=<0.0001
 Glimepiride or glibenclamide (in the past 6 months)0.99 (0.96 to 1.02);
p=0.3555
1.01 (0.98 to 1.04);
p=0.4844
1.02 (0.98 to 1.06);
p=0.3520
1.03 (0.99 to 1.08);
p=0.0998
1.00 (0.92 to 1.09);
p=0.9614
1.02 (0.93 to 1.11);
p=0.6751
0.96 (0.95 to 0.98);
p=<0.0001
0.98 (0.97 to 1.00);
p=0.0540
 Insulin (in the past 6 months)1.21 (1.18 to 1.24);
p=<0.0001
1.19 (1.17 to 1.22);
p=<0.0001
1.13 (1.10 to 1.17);
p=<0.0001
1.13 (1.10 to 1.17);
p=<0.0001
1.12 (1.06 to 1.19);
p=0.0001
1.12 (1.06 to 1.19);
p=0.0002
1.20 (1.19 to 1.22);
p=<0.0001
1.20 (1.18 to 1.21);
p=<0.0001
  • HF, heart failure.